The DSRU has recruited new research fellow, Samantha Lane, to start a new project to measure the impact of product withdrawals and other major pharmacovigilance actions on the public health burden since the implementation of the EU PV legislation in 2012. The results will be compared with those of two previous DSRU studies which looked at evidence used to support product withdrawals covering the periods 1999-2001 and 2002-2011.
One of the key priorities of PRAC’s Strategy on Measuring the Impact of Pharmacovigilance Activities (adopted January 2016) was the creation of an ENCePP Special Interest Group (SIG) on Impact, of which DSRU Director, Prof Saad Shakir, is a member. Sam’s project will form the DSRU’s contribution to the ENCePP SIG.
Sam is pictured here (R) with Saad Shakir and Liz Lynn.
- Quantitative measurement of the impact of Pharmacovigilance decisions
- Designing studies for risk management plans that are acceptable to European regulators
- GP Masterclass is a huge success!
- The DSRU will be exhibiting at the RPGP Annual Conference
- DSRU conducts 3rd flu vaccine safety surveillance study